Developments towards antiviral therapies against enterovirus 71

被引：80

作者：

Wu, Kan X. ^{[1
]}

Ng, Mary M. -L. ^{[1
]}

Chu, Justin J. H. ^{[1
]}

机构：

[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Natl Univ Hlth Syst, Dept Microbiol, Singapore 117595, Singapore

来源：

DRUG DISCOVERY TODAY | 2010年 / 15卷 / 23-24期

关键词：

SELECTIN GLYCOPROTEIN LIGAND-1; IN-VITRO ACTIVITY; PYRIDYL IMIDAZOLIDINONES; RNA INTERFERENCE; BROAD-SPECTRUM; CAPSID-BINDING; POLIOVIRUS; INHIBITORS; PROTEIN; INFECTION;

D O I：

10.1016/j.drudis.2010.10.008

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Enterovirus 71 (EV71) has emerged as a clinically important neurotropic virus that can cause acute flaccid paralysis and encephalitis, leading to cardiopulmonary failure and death. Recurring outbreaks of EV71 have been reported in several countries. The current lack of approved anti-EV71 therapy has prompted intense research into antiviral development. Several strategies - ranging from target-based chemical design to compound library screenings - have been employed, while others revisited compound series generated from antiviral developments against poliovirus and human rhinoviruses. These efforts have given rise to a diversity of antiviral candidates that include small molecules and non-conventional nucleic-acid-based strategies. This review aims to highlight candidates with potential for further clinical development based on their putative modes of action.

引用

页码：1041 / 1051

页数：11

共 82 条

[1] INVITRO ACTIVITY OF PIRODAVIR (R-77975), A SUBSTITUTED PHENOXY-PYRIDAZINAMINE WITH BROAD-SPECTRUM ANTIPICORNAVIRAL ACTIVITY [J].